The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

ConditionsLymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)AML (Acute Myelogenous Leukemia)Myeloma Multiple B-ALL T-ALL/Lymphoma T-lymphocyte Lymphoma

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorTianjin Medical University General Hospital

About this trial

This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy of CAR-T cell injections for the treatment of relapsed/refractory malignant hematological neoplasms in subjects.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）

Treatment groups

90 Participants

are divided into 1 treatment group

Sponsors and collaborators

Tianjin Medical University General Hospital

Lead sponsor

Hebei Taihe Chunyu Biotechnology Co., Ltd

Collaborator

Source ClinicalTrials.gov